The rise of Viagra and its impact on the pharmaceutical landscape presents a complex question for investors. While the first sales figures were remarkable, the exclusivity has lapsed, leading to a flood of off-brand alternatives that are chipping away at earnings. In addition, the sector is facing difficulties related to population trends and chang